Genomic abnormalities of waldenström macroglobulinemia and related low-grade B-cell lymphomas

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Waldenström macroglobulinemia (WM) is a lymphoproliferative disease characterized by a heterogeneous lymphoplasmacytic bone marrow infiltrate and monoclonal immunoglobulin M production. WM shows similarities in presentations with related B-cell malignancies, sometimes making it difficult to distinguish them. To better characterize the genetic basis of WM, we performed a comparative genomic analysis with the related entities, lymphoplasmacytic lymphomas without monoclonal immunoglobulin M protein, marginal zone lymphomas, chronic lymphocytic leukemia, and monoclonal gammopathy of undetermined significance. Overall, WM shows a very stable karyotype and shares most of the chromosomal abnormalities with most of the indolent B-cell malignancies. Trisomy 4 is unique to WM; however, no candidate genes have been identified in the chromosome. Abnormalities that affect myeloid differentiation primary response 88 (MYD88) - interleukin-1 receptor-associated kinase 4 (IRAK4) and nuclear factor kappa B (NF-κB) signaling pathways were found in a significant proportion of WM cases, which suggest their relevance in the pathogenesis of the disease and opening new avenues that may be a guide to design novel therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)198-201
Number of pages4
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Waldenstrom Macroglobulinemia
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Immunoglobulin M
Lymphoma
B-Lymphocytes
Interleukin-1 Receptor-Associated Kinases
Monoclonal Gammopathy of Undetermined Significance
NF-kappa B
Trisomy
B-Cell Chronic Lymphocytic Leukemia
Karyotype
Chromosome Aberrations
Neoplasms
Chromosomes
Bone Marrow
Genes
Proteins

Keywords

  • Array-based comparative genomic hybridization
  • Low-grade B-cell lymphomas
  • Nuclear factor kappa B signaling pathway
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

@article{05abe0ccfaae4743aac656e40d711cdf,
title = "Genomic abnormalities of waldenstr{\"o}m macroglobulinemia and related low-grade B-cell lymphomas",
abstract = "Waldenstr{\"o}m macroglobulinemia (WM) is a lymphoproliferative disease characterized by a heterogeneous lymphoplasmacytic bone marrow infiltrate and monoclonal immunoglobulin M production. WM shows similarities in presentations with related B-cell malignancies, sometimes making it difficult to distinguish them. To better characterize the genetic basis of WM, we performed a comparative genomic analysis with the related entities, lymphoplasmacytic lymphomas without monoclonal immunoglobulin M protein, marginal zone lymphomas, chronic lymphocytic leukemia, and monoclonal gammopathy of undetermined significance. Overall, WM shows a very stable karyotype and shares most of the chromosomal abnormalities with most of the indolent B-cell malignancies. Trisomy 4 is unique to WM; however, no candidate genes have been identified in the chromosome. Abnormalities that affect myeloid differentiation primary response 88 (MYD88) - interleukin-1 receptor-associated kinase 4 (IRAK4) and nuclear factor kappa B (NF-κB) signaling pathways were found in a significant proportion of WM cases, which suggest their relevance in the pathogenesis of the disease and opening new avenues that may be a guide to design novel therapeutic approaches.",
keywords = "Array-based comparative genomic hybridization, Low-grade B-cell lymphomas, Nuclear factor kappa B signaling pathway, Waldenstr{\"o}m macroglobulinemia",
author = "Braggio, {Esteban D} and Rafael Fonseca",
year = "2013",
month = "4",
doi = "10.1016/j.clml.2013.02.015",
language = "English (US)",
volume = "13",
pages = "198--201",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Genomic abnormalities of waldenström macroglobulinemia and related low-grade B-cell lymphomas

AU - Braggio, Esteban D

AU - Fonseca, Rafael

PY - 2013/4

Y1 - 2013/4

N2 - Waldenström macroglobulinemia (WM) is a lymphoproliferative disease characterized by a heterogeneous lymphoplasmacytic bone marrow infiltrate and monoclonal immunoglobulin M production. WM shows similarities in presentations with related B-cell malignancies, sometimes making it difficult to distinguish them. To better characterize the genetic basis of WM, we performed a comparative genomic analysis with the related entities, lymphoplasmacytic lymphomas without monoclonal immunoglobulin M protein, marginal zone lymphomas, chronic lymphocytic leukemia, and monoclonal gammopathy of undetermined significance. Overall, WM shows a very stable karyotype and shares most of the chromosomal abnormalities with most of the indolent B-cell malignancies. Trisomy 4 is unique to WM; however, no candidate genes have been identified in the chromosome. Abnormalities that affect myeloid differentiation primary response 88 (MYD88) - interleukin-1 receptor-associated kinase 4 (IRAK4) and nuclear factor kappa B (NF-κB) signaling pathways were found in a significant proportion of WM cases, which suggest their relevance in the pathogenesis of the disease and opening new avenues that may be a guide to design novel therapeutic approaches.

AB - Waldenström macroglobulinemia (WM) is a lymphoproliferative disease characterized by a heterogeneous lymphoplasmacytic bone marrow infiltrate and monoclonal immunoglobulin M production. WM shows similarities in presentations with related B-cell malignancies, sometimes making it difficult to distinguish them. To better characterize the genetic basis of WM, we performed a comparative genomic analysis with the related entities, lymphoplasmacytic lymphomas without monoclonal immunoglobulin M protein, marginal zone lymphomas, chronic lymphocytic leukemia, and monoclonal gammopathy of undetermined significance. Overall, WM shows a very stable karyotype and shares most of the chromosomal abnormalities with most of the indolent B-cell malignancies. Trisomy 4 is unique to WM; however, no candidate genes have been identified in the chromosome. Abnormalities that affect myeloid differentiation primary response 88 (MYD88) - interleukin-1 receptor-associated kinase 4 (IRAK4) and nuclear factor kappa B (NF-κB) signaling pathways were found in a significant proportion of WM cases, which suggest their relevance in the pathogenesis of the disease and opening new avenues that may be a guide to design novel therapeutic approaches.

KW - Array-based comparative genomic hybridization

KW - Low-grade B-cell lymphomas

KW - Nuclear factor kappa B signaling pathway

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84877603050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877603050&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.02.015

DO - 10.1016/j.clml.2013.02.015

M3 - Article

C2 - 23477936

AN - SCOPUS:84877603050

VL - 13

SP - 198

EP - 201

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 2

ER -